AAAAAA

   
Results: 1-14 |
Results: 14
Predicting the unpredictable: Transmission of drug-resistant HIV
Authors: Blower, SM Aschenbach, AN Gershengorn, HB Kahn, JO
Citation: Sm. Blower et al., Predicting the unpredictable: Transmission of drug-resistant HIV, NAT MED, 7(9), 2001, pp. 1016-1020
Prototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine (Coviracil)
Authors: Rousseau, FS Kahn, JO Thompson, M Mildvan, D Shepp, D Sommadossi, JP Delehanty, J Simpson, JN Wang, LH Quinn, JB Wakeford, C van der Horst, C
Citation: Fs. Rousseau et al., Prototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine (Coviracil), J ANTIMICRO, 48(4), 2001, pp. 507-513
Outcomes of a trial of HIV-1 immunogen in patients with HIV infection - Reply
Authors: Kahn, JO Lagakos, S
Citation: Jo. Kahn et S. Lagakos, Outcomes of a trial of HIV-1 immunogen in patients with HIV infection - Reply, J AM MED A, 285(17), 2001, pp. 2193-2195
Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults
Authors: Barditch-Crovo, P Deeks, SG Collier, A Safrin, S Coakley, DF Miller, M Kearney, BP Coleman, RL Lamy, PD Kahn, JO McGowan, I Lietman, PS
Citation: P. Barditch-crovo et al., Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults, ANTIM AG CH, 45(10), 2001, pp. 2733-2739
Postexposure prophylaxis for human immunodeficiency virus infection after sexual or injection drug use exposure: Identification and characterization of the source of exposure
Authors: Roland, ME Martin, JN Grant, RM Hellmann, NS Bamberger, JD Katz, MH Chesney, M Franses, K Coates, TJ Kahn, JO
Citation: Me. Roland et al., Postexposure prophylaxis for human immunodeficiency virus infection after sexual or injection drug use exposure: Identification and characterization of the source of exposure, J INFEC DIS, 184(12), 2001, pp. 1608-1612
Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: The San Francisco PEP study
Authors: Kahn, JO Martin, JN Roland, ME Bamberger, JD Chesney, M Chambers, D Franses, K Coates, TJ Hatz, MH
Citation: Jo. Kahn et al., Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: The San Francisco PEP study, J INFEC DIS, 183(5), 2001, pp. 707-714
Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection
Authors: Altfeld, M Rosenberg, ES Shankarappa, R Mukherjee, JS Hecht, FM Eldridge, RL Addo, MM Poon, SH Phillips, MN Robbins, GK Sax, PE Boswell, S Kahn, JO Brander, C Goulder, PJR Levy, JA Mullins, JI Walker, BD
Citation: M. Altfeld et al., Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection, J EXP MED, 193(2), 2001, pp. 169-180
Longitudinal analysis of T-cell receptor gene use by CD8(+) T cells in early human immunodeficiency virus infection in patients receiving highly active antiretroviral therapy
Authors: Schito, AM Vittinghoff, E Hecht, FM Elkins, MK Kahn, JO Levy, JA Oksenberg, JR
Citation: Am. Schito et al., Longitudinal analysis of T-cell receptor gene use by CD8(+) T cells in early human immunodeficiency virus infection in patients receiving highly active antiretroviral therapy, BLOOD, 97(1), 2001, pp. 214-220
Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy - A randomized controlled trial
Authors: Davey, RT Murphy, RL Graziano, FM Boswell, SL Pavia, AT Cancio, M Nadler, JP Chaitt, DG Dewar, RL Sahner, DK Duliege, AM Capra, WB Leong, WP Giedlin, MA Lane, HC Kahn, JO
Citation: Rt. Davey et al., Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy - A randomized controlled trial, J AM MED A, 284(2), 2000, pp. 183-189
Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 x 10(6)/L CD4 cell counts - A randomized controlled trial
Authors: Kahn, JO Cherng, DW Mayer, K Murray, H Lagakos, S
Citation: Jo. Kahn et al., Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 x 10(6)/L CD4 cell counts - A randomized controlled trial, J AM MED A, 284(17), 2000, pp. 2193-2202
From the cell to the community: AIDS research in California
Authors: Moss, NE Lemp, G Bluthenthal, R Goldsmith, MA Haubrich, R Kahn, JO
Citation: Ne. Moss et al., From the cell to the community: AIDS research in California, WEST J MED, 173(2), 2000, pp. 119-121
Current questions in HIV/AIDS research in California - Clinical sciences
Authors: Moss, NE Lemp, G Bluthenthal, R Goldsmith, MA Haubrich, R Kahn, JO
Citation: Ne. Moss et al., Current questions in HIV/AIDS research in California - Clinical sciences, WEST J MED, 173(2), 2000, pp. 121-124
Antibody and cellular immune responses in breakthrough infection subjects after HIV type 1 glycoprotein 120 vaccination
Authors: Locher, CP Grant, RM Collisson, EA Reyes-Teran, G Elbeik, T Kahn, JO Levy, JA
Citation: Cp. Locher et al., Antibody and cellular immune responses in breakthrough infection subjects after HIV type 1 glycoprotein 120 vaccination, AIDS RES H, 15(18), 1999, pp. 1685-1689
Post-exposure prevention of HIV-1 infection
Authors: Kahn, JO
Citation: Jo. Kahn, Post-exposure prevention of HIV-1 infection, ANTIVIR TH, 3, 1998, pp. 45-47
Risultati: 1-14 |